- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
M Pharmaceutical Signs Chinese Manufacturer for Trimtec
M Pharmaceutical Inc. (CSE:MQ) announced today that is has entered into an agreement with Chinese manufacturer Rishena Co. Ltd. to produce their Trimtec gastric functional neuro-stimulation device.
M Pharmaceutical Inc. (CSE:MQ) announced today that is has entered into an agreement with Chinese manufacturer Rishena Co. Ltd. to produce their Trimtec gastric functional neuro-stimulation device.
As quoted in the press release:
M Pharmaceutical Inc. has entered into a manufacturing supply agreement with Rishena Co. Ltd. of Changzhou, China, to manufacture the company’s Trimtec gastric functional neuro-stimulation device. Under the terms of the agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharmaceutical for the North and South American markets. The devices will be fully programmable and rechargeable through an abdominal belt. Rishena commits, at its expense, to obtain ISO 13485 certification(1) for Trimtec manufacturing prior to the Company’s commercial launch of Trimtec.
M Pharmaceutical President and CEO of M Pharma Dr. Martin Mintchev is quoted as saying:
Our agreement with Rishena is an important step forward in the development of Trimtec for the North and South American markets, we are delighted to collaborate with an experienced and respected medical device manufacturer such as Rishena and look forward to successful collaboration with them.
Click here for the full M Pharmaceutical Inc. (CSE:MQ) press release.
Click here for the M Pharmaceutical Inc. (CSE:MQ) profile.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â